Back to top
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Abbott Laboratories (ABT) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Abbott Laboratories (ABT) - free report >>
Image: Bigstock
Company News for April 20, 2017
• Shares of Lam Research Corporation (LRCX - Free Report) gained 6.9% after the company reported third-quarter fiscal 2017 non-GAAP earnings of $2.80 per share, which surpassed the Zacks Consensus Estimate of $2.54
• Facebook’s shares advanced 0.9% after it announced a new cameras-based augmented reality platform.
• Shares of Ultragenyx Pharmaceutical Inc (RARE - Free Report) gained 1.4% after the company declared positive data from a phase III study evaluating its pipeline candidate burosumab (KRN23) in adults with X-linked hypophosphatemia (XLH)
• Abbott Laboratories’ (ABT - Free Report) shares gained 0.4% after the company reported first quarter revenues of $6.33 billion which has surpassed the Zacks Consensus Estimate for revenues of $6.11 billion